Prenetics Global Ltd director Cheng Yin Pan filed an initial ownership report showing indirect holdings through M13 Capital Management Holdings Limited. The filing lists 75,021 Class A Ordinary Shares and 15,873 Restricted Stock Units, each RSU representing one Class A Ordinary Share vesting on May 17, 2026.
Prenetics Global Ltd Chief Financial Officer Hoi Chun Lo reported his initial equity holdings. He directly owns 487,462 Class A Ordinary Shares and two groups of Restricted Stock Units that can convert into 15,272 and 32,736 Class A Ordinary Shares at nominal exercise prices, with vesting in 2026 and expirations in 2030 and 2032.
Prenetics Global Limited announced that its Board of Directors has authorized a share repurchase program of up to $40 million of its Class A Ordinary Shares over a 12‑month period. This follows open‑market purchases by executives totaling approximately $2.75 million of personal capital across recent post‑earnings trading windows.
The company reports approximately $164 million in total adjusted liquidity as of March 1, 2026 and zero debt, supported by cash, fixed‑income funds, digital assets and divestiture proceeds. Its IM8 brand is targeting $180 million to $200 million in 2026 full‑year revenue and adjusted EBITDA profitability by Q4 2027, and the buyback may be executed via open‑market, block or negotiated purchases, including under Rule 10b5‑1 trading plans.
Prenetics Global Limited reported that its executive leadership team completed a second round of open market purchases of Prenetics common stock during the week of February 23–27, 2026, following the release of its 2025 year-end results. Executives acquired 76,060 shares for an aggregate of about $1,301,000, at an average price of roughly $17.11 per share.
CEO Danny Yeung bought 42,282 shares for approximately $750,000, CFO Stephen Lo bought 15,603 shares for about $250,000, CMO Rahul Ramchand bought 15,000 shares for about $251,000, and President of Americas David Vanderveen bought 3,175 shares for about $50,000. Together with a prior round after the November 2025 earnings release, leadership has now personally invested roughly $2.75 million in Prenetics shares.
The company highlights the growth of its IM8 consumer health brand, which surpassed $100 million in annualized recurring revenue within 11 months and is sold in more than 30 countries.
Prenetics Global Limited reported record 2025 results driven by its IM8 consumer health brand. Full-year revenue jumped to $92.4 million, up 479.7% year over year, with fourth-quarter revenue at $36.6 million, a 457.1% increase, as IM8 became the main growth engine.
IM8 delivered $60.1 million of 2025 revenue and reached about $120 million in annualized recurring revenue by December 2025, with December monthly revenue at $10.0 million and gross margin near 60%. Company-wide adjusted EBITDA loss narrowed to $13.0 million for 2025 and $2.3 million in Q4, showing improving operating leverage despite heavy marketing spend.
Prenetics completed divestitures of ACT Genomics, Europa and its 35% Insighta stake, lifting total adjusted liquidity to $171.1 million as of February 15, 2026, with no debt. Management reaffirmed 2026 IM8 revenue guidance of $180–$200 million and outlined a path toward adjusted EBITDA profitability by the fourth quarter of 2027.
Prenetics Global Limited reports a Board change and a sharpened strategic focus on its IM8 health and longevity brand. Director Andy Cheung resigned effective February 16, 2026, with the company stating his departure was not due to any disagreement. As part of its renewed focus, Prenetics has discontinued any future purchases of Bitcoin or other cryptocurrencies effective December 4, 2025.
The company appointed Dr. Darshan Shah, a longevity expert and health-tech CEO, as an independent director effective February 16, 2026, and he will also serve on key Board committees. Prenetics highlights IM8’s rapid growth, noting the brand surpassed $100 million in annualized recurring revenue within 11 months and is now sold in more than 30 countries.
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for total cash proceeds of $70 million, providing a substantial, non‑dilutive cash inflow and strengthening its balance sheet.
As of February 15, 2026, Prenetics reported total adjusted liquidity of $171.1 million, including $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances and $35.2 million in Bitcoin, while operating with zero outstanding debt. Management frames this divestiture as the final major step in a strategic shift to focus on IM8, its fast‑growing consumer health and longevity brand, supporting global expansion and product innovation. The company plans to discuss its financial position and outlook with fourth‑quarter and full‑year 2025 results, scheduled for pre‑market release on February 18, 2026.